GAfPA Blog

The GAfPA Patient Advocacy Blog

Regulators Stand Up for Biosimilars

Development of biosimilars has expanded patients’ treatment options by offering innovative medicine at lower costs than traditional biologics. So why are some nations slow to adopt biosimilars?

Patients at the Heart of New Cholesterol Guidelines

The European Society of Cardiology has released new guidelines recommending that patients lower their LDL cholesterol to reduce their risk of cardiovascular disease. But the guidelines don’t just reinforce an important truth. They make it actionable for patients.

Sign up to receive updates from GAfPA